Utility of warning signs in guiding admission and predicting severe disease in adult dengue by Yee-Sin Leo et al.
RESEARCH ARTICLE Open Access
Utility of warning signs in guiding admission and
predicting severe disease in adult dengue
Yee-Sin Leo1,2,3*, Victor C Gan1, Ee-Ling Ng1, Ying Hao1, Lee-Ching Ng4, Kwoon-Yong Pok4, Frederico Dimatatac1,
Chi-Jong Go1 and David C Lye1,3
Abstract
Background: The recommendation from the 2009 World Health Organization guidelines for managing dengue
suggests that patients with any warning sign can be hospitalized for observation and management. We evaluated
the utility of using warning signs to guide hospital admission and predict disease progression in adults.
Methods: We conducted a prospective cohort study from January 2010 to September 2012. Daily demographic,
clinical and laboratory data were collected from adult dengue patients. Warning signs were recorded. The
proportion of admitted patients using current admission criteria and warning signs was compared. The sensitivity,
specificity, positive and negative predictive values of warning signs in predicting disease progression were also
evaluated.
Results: Four hundred and ninety-nine patients with confirmed dengue were analyzed. Using warning signs
instead of the current admission criteria will lead to a 44% and 31% increase in admission for DHF II-IV and SD
cases respectively. The proportion of non-severe dengue cases which were admitted also increased by 32% for non
DHF II-IV and 33% for non-SD cases. Absence of any warning signs had a NPV of 91%, 100% and 100% for DHF I-IV,
DHF II-IV and SD. Of those who progressed to severe illness, 16.3% had warning signs on the same day while 51.3%
had warning signs the day before developing severe illness, respectively.
Conclusions: Our findings demonstrated that patients without any warning signs can be managed safely with
ambulatory care to reduce hospital resource burden. No single warning sign can independently predict disease
progression. The window from onset of warning sign to severe illness in most cases was within one day.
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Background
Dengue is the most common arboviral infection. It has a
wide disease spectrum, ranging from a self-limiting fever
to severe disease with fatal outcome. The World Health
Organization (WHO) estimates that 2.5 billion people
are at risk of dengue. A recent model estimates 390 mil-
lion infections annually with 96 million cases of clinically
apparent disease [1]. More than half a million people de-
velop severe illness, i.e., dengue hemorrhagic fever (DHF)
or dengue shock syndrome (DSS) or severe dengue (SD).
The case fatality rate reported for DHF from 2000–2007
in the Americas was 1.2% [2].
The WHO published two sets of guidelines for man-
aging dengue: the 1975–1997 guidelines and the recent
2009 guidelines. In the 1975–1997 guidelines, dengue se-
verity was categorized into dengue fever (DF), DHF and
DSS [3]. To be classified as DHF, all four of the follow-
ing requirements: fever, hemorrhagic manifestations,
thrombocytopenia and plasma leakage must be met.
This classification was, however, not inclusive enough
for all forms of severe outcomes [4]. The 2009 WHO
guidelines categorized disease severity into dengue with-
out warning sign(s) (WS), dengue with WS and SD [2].
The 2009 WHO guidelines proposed using WS as indi-
cators for disease progression. The WS comprised abdom-
inal pain, persistent vomiting, clinical fluid accumulation,
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mucosal bleed, lethargy, hepatomegaly (liver enlargement
by >2 cm) and an increase in hematocrit, concurrent with
a rapid decrease in platelet count [2]. The WHO recom-
mended patients with any WS be hospitalized for observa-
tion and management.
Singapore, an economically well-developed city in
South-east Asia, has predominantly adult dengue cases
[5,6]. We assessed the utility of WS in guiding hospital
admission and evaluated its predictive value for disease
progression among adults. In a retrospective study, we
previously reported that persistent vomiting, hepatomeg-
aly, clinical fluid accumulation, hematocrit rise together
with platelet decrease were highly specific for predicting
DHF and SD; however none of the WS were sensitive
[7]. Notably, in the absence of any WS, the negative pre-
dictive value was 96% and 97% for DHF and SD respect-
ively, suggesting that disease progression was extremely
unlikely in the absence of any WS. We validated the
findings in this prospective study aiming to assess the
utility of WS in guiding hospital admission and predict-
ing disease progression to DHF and SD.
Methods
Patients
We enrolled adult patients who consented to take part
in the Prospective Adult Dengue Study, a cohort study
of acutely febrile adults at the Communicable Disease
Center (CDC), Tan Tock Seng Hospital, Singapore from
January 2010 to September 2012. These comprised re-
ferrals for fever for investigation from the emergency
department (ED), other medical institutions, or self-
referral to the CDC. Inclusion criteria were age 18 years
and above with acute undifferentiated febrile illness
(recorded temperature >375°C with no alternative clin-
ical diagnosis). Pregnant women were excluded from
the study.
This study compared the baseline characteristics and
outcomes of two cohorts; those admitted from ED who
were enrolled as inpatients (ED cohort) and those ini-
tially enrolled in outpatient setting at the research clinic
(outpatient cohort). The outpatient cohort was the basis
to evaluate the utility of WS in guiding admission. The
entire cohort was analyzed to assess the predictive value
of WS for disease progression. All outpatients were man-
aged at the Infectious Disease Research Clinic at CDC.
Outpatients were managed by three trained Medical
Officers on a daily basis during acute illness until ini-
tiation of the recovery phase and reviewed at 21–
30 days after study enrolment. Decision to admit pa-
tients from both the research clinic and ED were
based on the published hospital admission criteria [8]
and the attending physician’s judgment. Criteria for
recommending admission include: platelet count ≤50 000/
mm3, serum hematocrit ≥50%, systolic blood pressure
≤90 mmHg, postural drop in blood pressure >20 mmHg,
pulse ≥100/min, clinical bleeding (except petechiae), pa-
tients with severe abdominal pain and persistent vomiting,
elderly patients with comorbidities, and whether patients
fulfilled our DHF predictive model [9,10].
To evaluate the utility of WS in guiding admission,
we compared admission based on published admission
criteria and Medical Officers’ judgment with alternative
hypothetical scenario of WS-guided admission. The clin-
ical outcomes were categorized into three groups (i) DHF
I-IV, (ii) DHF II-IV as defined by the WHO 1997
guidelines [3] and (iii) SD as defined in WHO 2009
guidelines [2].
Dengue viral infection was confirmed by RT-PCR
[11] or NS1 detection by Dengue NS1 Ag Strip (Bio-
Rad Laboratories, Marnes-la-Coquette, France) at the
Environment Health Institute, Singapore, a WHO Col-
laborating Center for Reference and Research on Arbo-
virus and their Associated Vectors. Detailed demographic,
clinical, and laboratory data were prospectively collected
according to research protocols. Warning signs were also
recorded.
Warning signs
Warning signs assessed comprised abdominal pain (or
tenderness), persistent vomiting, mucosal bleeding, clin-
ical fluid accumulation, hepatomegaly (>2 cm) and in-
crease in hematocrit (with concurrent decrease in platelet)
[2]. We opted to exclude lethargy as almost all patients
reported subjective lethargy. Lethargy as a WS was also
removed in our previous analysis due to ambiguity in
patients’ interpretation of lethargy and lack of objective
differentiation from tiredness [7]. The sensitivity (Sn), spe-
cificity (Sp), positive predictive value (PPV) and negative
predictive value (NPV) of each WS for predicting disease
progression was evaluated.
Clinical outcomes
We utilized both sets of the WHO guidelines in defining
disease severity. DHF was defined as per WHO 1997 guide-
lines, namely concomitant high fever, thrombocytopenia,
hemorrhagic manifestations and plasma leakage [3]. Plasma
leakage was determined by physical examination or chest
radiography showing fluid accumulation or hematocrit
change of ≥20% or hypoproteinemia. DHF grade I was de-
fined as presence of mild bleeding phenomena such as
petechiae, DHF II additionally required the occurrence of
spontaneous bleeding such as mucosal or gastrointestinal
bleeding. All DHF III and IV cases were classified as
DSS. For DSS, DHF cases required either (i) tachycardia
(pulse >100/minute) with narrow pulse pressure (<20mmHg)
or (ii) systolic blood pressure (SBP) <90 mmHg [12].
SD was defined as per WHO 2009 guidelines namely
cases with severe plasma leakage (shock, fluid accumulation
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with respiratory distress), severe bleeding or severe organ
impairment [2].
Statistical analysis
Categorical variables were described as absolute num-
bers and percentages. Chi-square tests were used to
compare categorical variables between groups of differ-
ent clinical outcomes. Median values and percentile
ranges were used in descriptive analysis for continuous
variables. Wilcoxon or t-tests were used for hypothesis
testing.
To analyze proportion of cases admitted when compar-
ing admission based on published criteria with WS-guided
admission, patients were classified into three categories of
severe illness; (i) DHF I-IV, (ii) DHF II-IV or (iii) SD. Pro-
portions of admitted severe and non-severe cases were
compared between admission practices (current practice
versus (vs) WS-guided). For predicting clinical outcomes
of DHF I-IV, DHF II-IV and SD, patients with presence of
WS and severe dengue were classified as true positives
(TP). When assessing such prediction of clinical outcome,
cases already with severe outcome on enrolment were ex-
cluded from analysis. Patients with WS but who did not
progress to severe dengue were classified as false positives
(FP). Sensitivity (Sn), specificity (Sp), positive predictive
value (PPV) and negative predictive value (NPV) were cal-
culated using WS to predict the clinical outcomes of DHF
I-IV, DHF II-IV and SD. The performance of using indi-
vidual WS and combinations of two and three WS were
tested. All statistical analyses were performed in the R
statistical environment and conducted at the significance
level of 0.05.
Ethics approval
Ethical approval was provided by the Domain Specific
Review Board of the National Healthcare Group, Singapore
(DSRB/E/2009/432). Written informed consent was ob-
tained from all subjects.
Results
Demographics
Four hundred and ninety-nine patients with confirmed
dengue were enrolled and analyzed in this study. Three
hundred and seventy-six patients were recruited from
the research clinic and were described as the “out-
patient” cohort. The remaining 123 patients were re-
cruited after admission from ED and described as the
“ED” cohort. Of the outpatient cohort, 77 patients were
subsequently admitted while 299 patients continued
their treatment as outpatients.
The demographics between the two cohorts were
similar except a small difference in the median age of
the ED cohort. There were significantly more DHF pa-
tients (p < 0.001) in ED cohort (Table 1).
In the ED cohort, 69 (56.1%) had at least one WS. The
frequencies of WS did not differ significantly between
gender (p = 0.64) and age (p = 0.88). Patients were unwell
for a median of 6 days (5th – 95th percentile; 3 – 8 days)
at the time of enrolment and this did not differ signifi-
cantly between patients with and without WS (p = 0.36)
(Table 2).
In the outpatient cohort of 376 cases, 203 (54%) had at
least one WS, 77 (20.5%) were admitted and 70 (18.6%)
fulfilled DHF criteria. Of these 70 DHF cases, 6 cases
were classified as DSS. Independently, 13 would be clas-
sified as SD using WHO 2009 classification (Table 2).
Three DSS patients were not admitted. Two had single
readings of transient hypotension (systolic blood pres-
sure less than 90 mmHg) while the third had persistent
low baseline blood pressure. All three remained clinically
stable throughout the entire course of illness. Within the
same cohort, there were another 4 SD patients who were
not admitted. Three reported menorrhagia without the
need for transfusion and one had isolated raised trans-
aminases with AST 1040 U/L and ALT 1029 U/L. Their
conditions improved during outpatient care and all four
were also clinically stable throughout the entire course
of illness. There was a single mortality, previously published
as a case report [13]. He was admitted because of loss
of appetite, severe vomiting, nausea, malaise, mild head-
aches and dizziness. He was alert and hemodynamically
stable at the time of admission but became restless in the
ward and died abruptly less than twelve hours after admis-
sion. He did not fulfill DHF criteria. Post-mortem investi-
gation showed evidence of myocarditis.
Similarly, in the outpatient cohort, the frequencies of
WS did not differ significantly between gender (p = 0.67)
and age (p = 0.68). Most patients had illness onset of
6 days (5th – 95th percentile; 3 – 8 days) at enrolment;
this did not differ significantly between the group of pa-
tients with and without WS (p = 0.06) (Table 2).
In both cohorts, WS were present in significantly higher
proportion of cases with DHF. All patients with severe ill-
ness defined as DSS and SD had at least one WS except
for one DSS patient. This patient was classified as DSS
Table 1 Demographic comparison of ED and outpatient
cohorts
ED Outpatients P-value
N = 123 N = 376
Male 92 (74.8) 304 (81.0) 0.19
Age (years) 37 (22, 58) 33 (21, 47) 0.02
Illness day on recruitment 6 (3, 8) 6 (3, 8) 0.17
Warning signs 69 (56.1) 203 (54.0) 0.76
DHF 68 (55.3) 70 (18.6) <0.001
For categorical variables, absolute numbers (and the relative percentage) are
being indicated. For continuous variables, medians (and the relative 5th-95th
percentile) are being indicated. DHF = dengue hemorrhagic fever.
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with a single episode of hypotension (SBP <90 mmHg)
and evidence of plasma leakage comprising hypoproteine-
mia without >20% hematocrit change [12]. The statistical
significance of the observations was not tested in the SD
and DSS patients in both cohorts as the number of pa-
tients in these categories were too small. Of note, a signifi-
cantly higher proportion of those with WS were admitted
(p =0.01) (Table 2).
Hospital admission criteria and Medical Officers’
judgment vs WS-guided admission
Admission based on the approach of using the hos-
pital admission criteria and Medical Officers’ judg-
ment was compared with the hypothetical scenario of
WS-guided admission (Table 3). Although WS-guided
admission included all severe dengue case (DHF II-IV
and SD), WS-guided admission would lead to an in-
crease in proportion admitted of 44% and 31% for
DHF II-IV and SD, respectively. The proportion of
non-severe dengue patients who was admitted also
increased by 32% for non DHF II-IV and 33% for
non-SD patients. The increase in admissions was sig-
nificant in all categories of dengue patients, except
for SD patients.
WS in predicting disease progression
Mucosal bleeding and abdominal pain were the two
most common WS at 75.9% and 43.3%, respectively. In
analyzing the performance of individual WS in predict-
ing DHF and SD, we found mucosal bleeding had the
highest sensitivity (DHF I-IV: 61%; DHF II-IV: 100%; SD:
62%). The NPV for mucosal bleeding was 100% for DHF
II-IV and 98% for SD. However, both specificity and
PPV for prediction of DHF and SD were relatively low
(Table 4). Having any of the WS would have 100% sen-
sitivity in predicting DHF II-IV and SD. However, the
specificity was only 52% and 48% for DHF II-IV and
SD, respectively. The PPV of any WS was low at 21%
and 6% for DHF II-IV and SD, respectively. Notably,
the absence of any WS had NPV of 91%, 100% and
100% for DHF I-IV, DHF II-IV and SD, respectively.
Having two or three of the WS, however, decreased
the overall sensitivity and NPV in predicting DHF I-
IV, DHF II-IV and SD but the specificity and PPV in
predicting disease progression were increased in all
categories of disease (Table 4).
We further identified 49 cases in the outpatient cohort
who progressed to severe illness: 8 (16.3%) had WS the
same day as they progressed to severe illness and 25
Table 2 Comparison of demographic data and outcomes in ED and outpatient cohorts with and without warning signs
ED (N = 123) Outpatients (N = 376)
WS + ve (N = 69) WS -ve (N = 54) P-value WS + ve (N = 203) WS -ve (N = 173) P-value
Male 50 (72.5) 42 (77.8) 0.64 162 (79.8) 142 (82) 0.67
Age (years) 36 (23, 53) 37 (21, 60) 0.88 34 (22, 47) 32 (32, 48) 0.68
Illness day on recruitment 6 (3, 8) 6 (3, 8) 0.36 6 (3, 8) 6 (4, 9) 0.06
DHF I-IV 45 (65.2) 23 (42.6) 0.02 55 (27.0) 15 (8.7) <0.001
DSS (DHF III, IV) 6 (8.1) 1 (1.9) NA 6 (3.0) 0 NA
SD 7 (10.1) 0 NA 13 (6.4) 0 NA
Admission NA NA 52 (25.5) 25 (14.5) 0.01
For categorical variables, absolute numbers (and the relative percentage) are being indicated. For continuous variables, medians (and the relative 5th-95th
percentile) are being indicated.
WS Warning signs, DHF dengue hemorrhagic fever, DSS dengue shock syndrome, SD severe dengue.
Table 3 Proportion of severe vs non-severe dengue cases admitted from ambulatory care using either current
admission practice or using warning signs as admission criteria (percentage of cases (95% confidence interval))
DHF I-IV P-value Non-DHF I-IV P-value
Admission criteria + clinical judgment 59% (46%, 70%) 0.02 12% (8%, 16%)
<0.01
WS 79% (67%, 87%) 48% (43%, 54%)
DHF II-IV P-value Non-DHF II-IV P-value
Admission criteria + clinical judgment 56% (4%, 71%) <0.01 16% (12%, 20%)
<0.01
WS 100.0% (88%, 100%) 48% (43%, 54%)
SD P-value Non-SD P-value
Admission criteria + clinical judgment 69% (39%, 91%) 0.13 19% (15%, 23%)
<0.01
WS 100.0% (66%, 100%) 52% (47%, 58%)
WS Warning signs, DHF dengue hemorrhagic fever, SD severe dengue.
P-values indicate the significance of the difference in proportion between current admission practice and using warning signs as admission criteria.
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(51%) cases had WS one day before progressing to se-
vere illness (Figure 1).
We further analyzed mucosal bleeding as it was the
most frequently reported WS. Eighty-four percent and
68% of DF and DHF patients, respectively, had gingival
bleeding. Epistaxis was the next most frequent mucosal
bleeding event, followed by menorrhagia in both DF and
DHF patients. However, there was no significant difference
in the frequency of these mucosal bleeding events (namely
gingival bleeding, epistaxis, hemoptysis or hematuria) be-
tween DF and DHF patients (data not shown).
Discussion
The revised classification was well-received in a multi-
center survey conducted from February to November
2009. However, participants of the study also indicated
that the revised classification may result in over-admission
since the WS in the WHO 2009 guidelines was less spe-
cific for the diagnosis of probable dengue [14]. Several
other studies compared sensitivity of the two sets of the
WHO guidelines in classifying severe illness [15-18].
Three of these studies indicated that the new classification
was highly sensitive in identifying severe illness. In a
recently published study conducted in Lucknow, India,
the new set of guidelines identified 98% of all severe illness
[18]. Narvaez et al. [17] reported in a separate study
that the revised classification was highly sensitive in
identifying cases which need heightened care; however
it was noted that it was less specific and can no longer
differentiate the pathogenic entity of DHF and DSS. In
addition, they noted that DENV2 was significantly associ-
ated with DHF/DSS but not with the revised classification
for severe illness. Similar findings were reported in other
pediatric studies [19,20].
Kalayanarooj et al., also noted that WHO 2009 classifica-
tion may have been too sensitive and would have created
about 2 times additional workload to medical personnel
[15]. This is undesirable particularly in resource-limited
endemic regions. Our study suggested a 2–3 fold increase
in workload if the hospital adopted WS-guided admission
over the current hospital admission criteria and clincian’s
judgment.
The WHO recommended that dengue patient with any
WS be admitted for close observation [2]. In Singapore,
dengue incidence averages 5000 cases annually since 2010
[21-23]. The admission rate to public hospitals was ap-
proximately 37% of all cases notified to Ministry of Health
in 2012 (unpublished data). This was a drop from approxi-
mately 80% admission rate in 2000–2004 [8]. The drop in
admission may be due to the establishment of a national
Table 4 Performance of individual warning signs in predicting DHF and SD in outpatients
Warning sign DHF I-IV (N = 70) DHF II-IV (N = 43) SD (N = 13)
Sn Sp PPV NPV Sn Sp PPV NPV Sn Sp PPV NPV
Abdominal pain (N = 88) 31 78 25 83 37 78 18 91 38 77 6 97
Persistent vomiting (N = 16) 7 96 31 82 9 96 25 89 23 96 19 97
Clinical fluid accumulation (N = 1) 1 100 100 82 0 100 0 89 0 100 0 97
Mucosal bleeding (N = 154) 61 64 28 88 100 67 28 100 62 60 5 98
Hepatomegaly (> 2 cm) (N = 2) 1 100 50 82 0 99 0 89 0 99 0 97
↑ in hematocrit; rapid ↓ of platelet (N = 10) 14 100 100 84 9 98 40 89 31 98 40 98
Any warning sign (N = 203) 79 52 27 91 100 52 21 100 100 48 6 100
Two warning signs (N = 61) 33 88 38 85 47 88 33 93 46 85 10 98
Three warning signs (N = 7) 6 99 57 82 9 99 57 89 8 98 14 97
Numbers indicated are percentages.
Sn sensitivity, Sp specificity, PPV Positive predictive value, NPV Negative predictive value.
Combinations of two warning signs include: Abdominal pain and mucosal bleeding; Abdominal pain and persistent vomiting; Abdominal pain and hepatomegaly;
Abdominal pain and clinical fluid accumulation; Mucosal bleeding and persistent vomiting; Mucosal bleeding and hepatomegaly; Mucosal bleeding and change in
hematocrit level; Abdominal pain and change in hematocrit level.
Combinations of three warning signs include: Abdominal pain, mucosal bleeding and persistent vomiting; Abdominal pain, mucosal bleeding and change in
hematocrit level.
WS Warning signs, DHF dengue hemorrhagic fever, SD severe dengue.
Figure 1 Duration from onset of warning signs to DHF in
outpatients (N = 49).
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guideline for management of dengue patients in 2005 [24].
In this study, we observed that 54% of the outpatient co-
hort had WS. In contrast, using the hospital admission
criteria and clinical judgment, only 25.6% of outpatients
with WS were admitted. Patients with WS who were man-
aged as outpatients did not have any adverse outcomes
did just as well. Although some cases with WS who were
classified as having severe illness were not admitted, none
had adverse outcomes. This could be argued as under-
hospitalization and this practice cannot be generalizable
to healthcare settings lacking dedicated dengue care units
that can closely monitor the cases. We found that with
trained staff reviewing cases daily, subjects with isolated
elevation of transaminases or a single brief hypotensive
episode can be safely managed in the outpatient setting.
The increased resources needed for the higher
hospitalization rates if WS were used as admission criteria
have to be balanced against the careful individualized
management of cases in ambulatory care using clinical
judgment to determine admission.
Although the presence of any WS was strongly associ-
ated with severe outcomes, it lacked specificity and had
a low PPV. We previously reported in a large retrospect-
ive study that absence of any WS gave a high NPV for
severe illness progression [7]. The findings of this pro-
spective study supported our previous results. In the ab-
sence of any WS, NPV was 91%, 100% and 100% for
DHF I-IV, DHF II-IV and SD. These data supported the
proposal of using WS to screen those who do not need
hospital admission. Tsai et al., had also previously sup-
ported the proposal of outpatient treatment for dengue
patients who do not have any WS [16]. For patients with
WS, we demonstrated that with close monitoring it was
safe to continue outpatient management in majority of
the cases in our center. Nonetheless, the decision to
admit patients with WS would still be dependent on ac-
cess to healthcare facilities and local practice.
It is critical to understand the temporal onset of WS
to severe illness and the frequencies of individual WS in
severe illness [7,25]. In a multi-center study, Alexander
et al., had noted that in the majority of patients who de-
veloped severe illness, WS developed 1 day prior to the
requirement for intervention and 4–7 days since devel-
opment of illness [25]. They observed that abdominal
pain, lethargy, decreased platelet count and mucosal
bleeding were strongly associated with development of
severe illness. At least one of these WS was also found
to be associated with severe illness in several other stud-
ies [7,16,26]. We found that WS typically occurred one
day prior to the development of severe illness. The win-
dow to provide intervention can be challenging in areas
where healthcare facilities are remote from place of resi-
dence. We reported a single fatality that had WS one
day before his death, highlighting the possible rapid
progression of dengue disease [13]. With regard to mu-
cosal bleeding as the most frequent WS, its frequency
was not statistically different between the DF and DHF
patients. Individual bleeding symptoms were also not
statistically different between DF and DHF patients. Our
observation would support the lack of evidence for a sig-
nificantly higher rate of hemorrhage in DHF patients.
The limitations of this study include the tertiary set-
ting of the hospital that does not allow the results from
this study to be generalized to primary healthcare set-
tings where medical expertise and resources are less
readily available, the small sample size which prevented
detailed analysis on the performance of each individual
WS and the adult cohort that cannot be generalized to
the pediatric population. Because DENV-2 was the pre-
dominant serotype during the study period and our co-
hort had low prevalence of co-morbidities, serotypes and
presence of co-morbidities in relation to WS and disease
outcomes were not evaluated.
Conclusions
This prospective study demonstrated a strong correlation
between absence of WS and disease non-progression. The
absence of WS can therefore be utilized as an indicator to
safely manage cases in outpatient settings. However, none
of the individual WS can independently predict disease
progression but having two or more WS warrants close
observation. Further work in identifying other laboratory
and/or clinical markers is needed to improve dengue
management.
Competing interests
Yee-Sin Leo was a medical advisor to Sanofi-Pasteur for a dengue vaccine
trial. The authors declare that they have no competing interests.
Authors’ contributions
Concept, design, data acquisition, data analysis and data interpretation. YSL:
Concept design and data interpretation; VCG, LCN, KYP, DF and CJG: Data
acquisition; ELN: Data interpretation; YH: Data analysis; DCL: Concept design.
Drafting or revising manuscript. YSL, VCG ELN: Drafting and revising; YH, LCN,
KYP, DF, CJG, DCL: Revising. All authors read and approved the final
manuscript.
Acknowledgements
We thank Professor Kee Seng Chia from the Saw Swee Hock School of Public
Health, National University of Singapore and Professor Kee Tai Goh from the
Ministry of Health, Singapore for providing useful advice on this study. We
also thank Dr. Siew Pang Chan from Department of Clinical Epidemiology,
Tan Tock Seng Hospital for providing comments on the statistical analysis for
this study. We are grateful to the staff at the CDC, who looked after the
dengue patients during the epidemics, and members in STOP Dengue
Translational Clinical Research and CDC who provided invaluable support in
data processing, management and administrative work.
Funding
This work is supported by the STOP Dengue Grant from the National Research
Foundation through National Medical Research Council (NMRC/TCR/005/2008).
The funders had no role in study design, data collection, analysis, decision to
publish or preparation of the manuscript.
Leo et al. BMC Infectious Diseases 2013, 13:498 Page 6 of 7
http://www.biomedcentral.com/1471-2334/13/498
Author details
1Department of Infectious Disease, Communicable Disease Center, Institute
of Infectious Disease and Epidemiology, Tan Tock Seng Hospital, Singapore,
Singapore. 2Saw Swee Hock School of Public Health, National University of
Singapore, Singapore, Singapore. 3Yong Loo Lin School of Medicine, National
University of Singapore, Singapore, Singapore. 4Environmental Health
Institute, National Environment Agency, Singapore; School of Biological
Science, Nanyang Technological University, Singapore, Singapore.
Received: 26 July 2013 Accepted: 17 October 2013
Published: 24 October 2013
References
1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM,
Brownstein JS, Hoen AG, Sankoh O, et al: The global distribution and
burden of dengue. Nature 2013. doi:10.1038/nature12060.
2. World Health Organization: Dengue: Guidelines for diagnosis, treatment,
prevention and control. Geneva: World Health Organization; 2009.
3. World Health Organization: Dengue: Guidelines for diagnosis, treatment,
prevention and control. Geneva: World Health Organization; 1997.
4. Srikiatkhachorn A, Gibbons RV, Green S, Libraty DH, Thomas SJ, Endy TP,
Vaughn DW, Nisalak A, Ennis FA, Rothman AL, Nimmannitaya S,
Kalayanarooj S: Dengue haemorrhagic fever: the sensitivity and specificity
of the WHO definition in identifying severe dengue cases in Thailand,
1994–2005. Clin Infect Dis 2010, 50:1135–1143.
5. Ooi EE, Hart TJ, Tan HC, Chan SH: Dengue sero-epidemiology in
Singapore. Lancet 2001, 357:685–686.
6. Ooi EE, Goh KY, Gubler DJ: Dengue prevention and 35 years of vector
control in Singapore. Emerg Infect Dis 2006, 12(6):887–893.
7. Thein TL, Gan VC, Lye DC, Yung CF, Leo YS: Utilities and limitations of the
world health organization 2009 warning signs for adult dengue severity.
PLoS Negl Trop Dis 2013, 7:e2023.
8. Lee LK, Earnest A, Carrasco LR, Thein TL, Gan VC, Lee VJ, Lye DC, Leo YS:
Safety and cost savings of reducing adult dengue hospitalization in
tertiary care hospital in Singapore. Trans R Soc Trop Med Hyg 2013,
107:37–42.
9. Lee VJ, Lye DCB, Sun Y, Fernandez G, Ong A, Leo YS: Predictive value of
simple clinical and laboratory variables for dengue hemorrhagic fever in
adults. J Clin Virol 2008, 42(1):34–39.
10. Lee VJ, Lye DC, Sun Y, Leo YS: Decision tree algorithm in deciding
hospitalization for adult patients with dengue haemorrhagic fever in
Singapore. Trop Med Int Health 2009, 14(9):1154–1159.
11. Lai YLCY, Tan HC, Yap HF, Yap G, Ooi EE, Ng LC: Cost-effective real-time
reverse transcriptase PCR (RT-PCR) to screen for dengue virus followed
by rapid single-tube multiplex RT-PCR for serotyping of the virus. J Clin
Microbiol 2007, 45(3):935–941.
12. Gan VC, Lye DC, Thein TL, Dimatatac F, Tan AS, Leo YS: Implications of
discordance in world health organization 1997 and 2009 dengue
classifications in adult dengue. PLoS One 2012, 8(4):e60946.
13. Marques N, Gan VC, Leo YS: Dengue myocarditis in Singapore: two case
reports. Infection 2013, 41(3):709–714.
14. Barniol J, Gaczkowski R, Barbato EV, da Cunha RV, Salgado D, Martinez E,
Segarra CS, Sandoval EBP, Mishra A, Laksono IS, Lum LCS, Martinez JG,
Nunez A, Balsameda A, Allende I, Ramirez G, Dimaano E, Thomacheck K,
Akbar NA, Ooi EE, Villegas E, Hien TT, Farrar J, Horstick O, Kroeger A,
Jaenisch T: Usefulness and applicability of the revised dengue case
classification by disease: multi-centre study in 18 countries. BMC Infect
Dis 2011, 11:106.
15. Kalayanarooj S: Dengue classification: current WHO vs. the newly
suggested classification for better clinical application? J Med Assoc Thai
2011, 94:74–84.
16. Tsai CY, Lee IK, Lee CH, Yang KD, Liu JW: Comparisons of dengue illness
classified based on the 1997 and 2009 world health organization
dengue classification schemes. J Microbiol Immunol Infect 2012.
doi:10.1016/j.jmii.2012.1007.1005.
17. Narvaez F, Gutierrez G, Perez MA, Elizondo D, Nunez A, Balmaseda A,
Harris E: Evaluation of the traditional and revised WHO classifications of
dengue disease severity. PLoS Negl Trop Dis 2011, 5:e1397.
18. Prasad D, Kumar C, Jain A, Kumar R: Accuracy and applicability of the
revised WHO classification (2009) of dengue in children seen at a
tertiary healthcare facility in northern India. Infection 2013. In Press.
19. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn
S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, et al: Dengue viremia
titer, antibody response pattern, and virus serotype correlate with
disease severity. J Infect Dis 2000, 181(1):2–9.
20. Balmaseda A, Hammond SN, Pérez L, Tellez Y, Saborío SI, Mercado JC,
Cuadra R, Rocha J, Pérez MA, Silva S, et al: Serotype-differences in clinical
manifestations of dengue. Am J Trop Med Hyg 2006, 74(3):449–456.
21. Ministry of Health, Singapore: Weekly Infectious Disease Bulletin, Week 52,
2010. http://www.moh.gov.sg/content/dam/moh_web/Statistics/Infectious_
Diseases_Bulletin/2010/December/2010_week_52.pdf.
22. Ministry of Health, Singapore: Weekly Infectious Disease Bulletin, Week 52,
2011. http://www.moh.gov.sg/content/dam/moh_web/Statistics/Infectious_
Diseases_Bulletin/2011/December/2011_week_52.pdf.
23. Ministry of Health, Singapore: Weekly Infectious Disease Bulletin, Week 52,
2012. http://www.moh.gov.sg/content/dam/moh_web/Statistics/Infectious_
Diseases_Bulletin/2012/December/2012_week_52.pdf.
24. College of Family Physician, Singapore: Primary care for management of
dengue/dengue haemorrhagic fever during an outbreak. http://www.moh.gov.
sg/content/dam/moh_web/Statistics/Infectious_Diseases_Bulletin/2012/
December/2012_week_52.pdf.pdf.
25. Alexander N, Balmaseda A, Coelho IC, Dimaano E, Hien TT, Hung NT, Jänisch
T, Kroeger A, Lum LC, Martinez E, et al: Multicentre prospective study on
dengue classification in four South-east Asian and three Latin American
countries. Trop Med Int Health 2011, 16(8):936–948.
26. Jayaratne SD, Atukorale V, Gomes L, Chang T, Wijesinghe T, Fernando S,
Ogg GS, Malavige GN: Evaluation of the WHO revised criteria for
classification of clinical disease severity in acute adult dengue infection.
BMC Res Notes 2012, 5:645.
doi:10.1186/1471-2334-13-498
Cite this article as: Leo et al.: Utility of warning signs in guiding
admission and predicting severe disease in adult dengue. BMC Infectious
Diseases 2013 13:498.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Leo et al. BMC Infectious Diseases 2013, 13:498 Page 7 of 7
http://www.biomedcentral.com/1471-2334/13/498
